Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Mons – page 17

640 clinical trials in Mons, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Mons at a glance
640
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

640 trials in Mons

Open in trial search

Study on Darolutamide and Radiation Therapy for Patients with Castration-Resistant Prostate Cancer and Oligometastases

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide
  • Sponsor:Unicancer

Study of MK-1084 and Pembrolizumab for First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer with KRAS G12C Mutation and High PD-L1 Levels

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:MK-1084
  • Sponsor:Merck Sharp & Dohme LLC

Study of Sacituzumab Tirumotecan and Pembrolizumab for Patients with Triple-Negative Breast Cancer Post-Surgery

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Study on Maintaining Remission in ANCA-Associated Vasculitis with Prednisone and Rituximab for Patients in Remission from Granulomatosis with Polyangiitis or Microscopic Polyangiitis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Hospices Civils De Lyon

Oral herpes+1

Recruiting

Study on the Effectiveness of 2LHERP in Reducing Recurrent Cold Sores in Patients with Frequent Outbreaks

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Ribonucleic Acid
  • Sponsor:Labo'Life Belgium

Study to Compare Datopotamab Deruxtecan with Rilvegostomig or Alone Against Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with High PD-L1 Levels

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Infliximab
  • Sponsor:AstraZeneca AB

Study on the Effectiveness of Abiraterone, Capivasertib, and Enzalutamide in Patients with Metastatic Prostate Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Karolinska Institutet

Colon cancer

Recruiting

Study on the Effectiveness of Chemotherapy with Folinic Acid, Fluorouracil, and Irinotecan for Patients with Stage III Colon Cancer After Surgery

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Centre Hospitalier Universitaire De Dijon

Study on Colchicine for Patients with Coronary Artery Disease After Percutaneous Coronary Intervention

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Colchicine
  • Sponsor:Az St-Jan Brugge-Oostende A.V.

Prostate cancer

Recruiting

Study on High-Risk Prostate Cancer Treatment Using Darolutamide, Relugolix, and Drug Combination for Eligible Patients

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide
  • Sponsor:Ziekenhuis Aan De Stroom

Study on Elacestrant for Treating ER+/HER2- Breast Cancer in Patients with ctDNA Relapse

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Study Comparing Telisotuzumab Vedotin and Docetaxel for Adults with Previously Treated Non-Squamous Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Mons

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on lung cancer treatments, including studies of combination therapies with BNT327 and investigations into both small cell and non-small cell variants. Additional research covers breast cancer and cervical cancer treatments.

  • Non-small cell lung cancer therapy optimization
  • Advanced solid tumors treatment
  • Lymphoma treatment innovations

Studies aim to improve survival rates and treatment effectiveness through targeted therapies and immunotherapy combinations.

02 Cardiovascular Studies

Comprehensive research into coronary artery disease and post-stroke treatments, evaluating new antiplatelet therapies and innovative stent technologies. Studies focus on reducing cardiovascular events and improving patient outcomes.

  • Acute coronary syndrome management
  • Stroke prevention strategies
  • Antiplatelet therapy optimization

Investigations aim to enhance treatment protocols and reduce cardiovascular complications.

03 Autoimmune Conditions

Groundbreaking research in multiple sclerosis and psoriatic arthritis treatments, evaluating novel therapeutic approaches including BTK inhibitors and biological treatments.

  • Progressive MS treatment development
  • Arthritis management innovations
  • Long-term therapy effectiveness

Focus on improving quality of life and disease management for patients with chronic autoimmune conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.